[1] |
WYNN T A, RAMALINGAM T R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease[J]. Nat Med,2012,18(7):1028-1040. |
[2] |
LIU H B, ZHAN X Y, XU G, et al. Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases[J]. Pharmacol Res,2021,164:105384. |
[3] |
HAN Z, LIU S, LIN H S, et al. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses[J]. Cancer Immunol Immunother,2019,68(7):1073-1085. |
[4] |
CHA J D, LEE J H, CHOI K M, et al. Synergistic effect between cryptotanshinone and antibiotics against clinic methicillin and vancomycin-resistant Staphylococcus aureus[J]. Evid Based Complement Alternat Med,2014,2014:450572. |
[5] |
MAO Y F, QU Y, WANG Q D. Cryptotanshinone reduces neurotoxicity induced by cerebral ischemia-reperfusion injury involving modulation of microglial polarization[J]. Restor Neurol Neurosci,2021,39(3):209-220. |
[6] |
ZHANG Y P, LUO F, ZHANG H X, et al. Cryptotanshinone ameliorates cardiac injury and cardiomyocyte apoptosis in rats with coronary microembolization[J]. Drug Dev Res,2021,82(4):581-588. |
[7] |
WANG W, ZHOU P H, HU W, et al. Cryptotanshinone hinders renal fibrosis and epithelial transdifferentiation in obstructive nephropathy by inhibiting TGF-β1/Smad3/integrin β1 signal[J]. Oncotarget,2017,9(42):26625-26637. |
[8] |
MA Y Z, LI H, YUE Z B, et al. Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4[J]. J Cardiovasc Pharmacol,2014,64(1):28-37. |
[9] |
ZHANG Y T, LU W T, ZHANG X L, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways[J]. Pharmacol Res,2019,147:104307. |
[10] |
WANG W, WANG X, ZHANG X S, et al. Cryptotanshinone attenuates oxidative stress and inflammation through the regulation of nrf-2 and NF-κB in mice with unilateral ureteral obstruction[J]. Basic Clin Pharmacol Toxicol,2018,123(6):714-720. |
[11] |
LIU M R, LÓPEZ DE JUAN ABAD B, CHENG K. Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies[J]. Adv Drug Deliv Rev,2021,173:504-519. |
[12] |
VERMOT A, PETIT-HÄRTLEIN I, SMITH S M E, et al. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology[J]. Antioxidants (Basel),2021,10(6):890. |
[13] |
CHANDRA S, EHRLICH K C, LACEY M, et al. Epigenetics and expression of key genes associated with cardiac fibrosis: NLRP3, MMP2, MMP9, CCN2/CTGF and AGT[J]. Epigenomics,2021,13(3):219-234. |
[14] |
DONG F, ABHIJIT T, JIWON L, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease[J]. Fibrogenesis Tissue Repair, 2012, 15(5(1)). |
[15] |
MA S T, YANG D C, WANG K Y, et al. Cryptotanshinone attenuates isoprenaline-induced cardiac fibrosis in mice associated with upregulation and activation of matrix metalloproteinase-2[J]. Mol Med Rep,2012,6(1):145-150. |
[16] |
LO S H, HSU C T, NIU H S, et al. Cryptotanshinone inhibits STAT3 signaling to alleviate cardiac fibrosis in type 1-like diabetic rats[J]. Phytother Res,2017,31(4):638-646. |
[17] |
FAN D, TAKAWALE A, LEE J, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease[J]. Fibrogenesis Tissue Repair,2012,5(1):15. |
[18] |
MARCONI G D, FONTICOLI L, RAJAN T S, et al. Epithelial-mesenchymal transition (EMT): the type-2 EMT in wound healing, tissue regeneration and organ fibrosis[J]. Cells,2021,10(7):1587. |
[19] |
KALLURI R, NEILSON E G. Epithelial-mesenchymal transition and its implications for fibrosis[J]. J Clin Invest,2003,112(12):1776-1784. |
[20] |
JIANG Y F, YOU F M, ZHU J, et al. Cryptotanshinone ameliorates radiation-induced lung injury in rats[J]. Evid Based Complement Alternat Med,2019,2019:1908416. |
[21] |
ROEHLEN N, CROUCHET E, BAUMERT T F. Liver fibrosis: mechanistic concepts and therapeutic perspectives[J]. Cells,2020,9(4):875. |
[22] |
ALTAMIRANO-BARRERA A, BARRANCO-FRAGOSO B, MÉNDEZ-SÁNCHEZ N. Management strategies for liver fibrosis[J]. Ann Hepatol,2017,16(1):48-56. |
[23] |
NAGAPPAN A, KIM J H, JUNG D Y, et al. Cryptotanshinone from the Salvia miltiorrhiza bunge attenuates ethanol-induced liver injury by activation of AMPK/SIRT1 and Nrf2 signaling pathways[J]. Int J Mol Sci,2019,21(1):265. |
[24] |
LAN H Y. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation[J]. Int J Biol Sci,2011,7(7):1056-1067. |
[25] |
段红梅, 吴志远, 江黎明. 隐丹参酮对人皮肤瘢痕胶原基因表达的影响[J]. 齐齐哈尔医学院学报, 2009, 30(3):267. |
[26] |
杨莉, 李雪莉, 宋静卉, 等. 隐丹参酮抑制模型兔耳增生性瘢痕的作用及机制[J]. 中国组织工程研究, 2021, 25(20):3150-3155. |
[27] |
LI Y, SHI S, GAO J X, et al. Cryptotanshinone downregulates the profibrotic activities of hypertrophic scar fibroblasts and accelerates wound healing: a potential therapy for the reduction of skin scarring[J]. Biomed Pharmacother,2016,80:80-86. |